Neurally mediated and direct effects of acetylstrophanthidin on canine skeletal muscle vascular resistance.
D000109:Acetylcholine / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002339:Carotid Arteries / Q000294:innervation; D004071:Digitalis Glycosides / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004285:Dogs; D004336:Drug Antagonism; D005260:Female; D006614:Hindlimb / Q000098:blood supply; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D009121:Muscle Denervation; D009132:Muscles / Q000098:blood supply*; D009475:Neurons, Afferent / Q000601:surgery; D010477:Perfusion; D010643:Phenoxybenzamine / Q000494:pharmacology; D011311:Pressoreceptors / Q000502:physiology*; D014628:Vagotomy; D014655:Vascular Resistance / Q000187:drug effects*; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D000317:Adrenergic alpha-Antagonists; D004071:Digitalis Glycosides; D014662:Vasoconstrictor Agents; D010643:Phenoxybenzamine; D001285:Atropine; D007545:Isoproterenol; D000109:Acetylcholine